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Background: The rates of muscle aches, sprains, and inflammation are significantly increased during pregnancy.
However, women are afraid to use systemic analgesics due to perceptions of fetal risks. Thus, topical products are
important alternatives to consider for those women. Of interest, Professional Therapy MuscleCare (PTMC) has shown
to be effective in alleviating the myofascial pain as reported in a randomized, placebo-controlled double-blinded
comparative clinical study of five topical analgesics. However, to date, there is no complete review or long-term
safety studies on the safety of these products during pregnancy and lactation. Thus, the aim of this article was to
review toxicological, developmental, and reproductive effects associated with the use of PTMC products.
Methods: We performed a systematic review on safety of PTMC from all toxicological articles investigating the
effects of PTMC’s ingredients. This search was conducted through medical and toxicological databases including,
Web of Science, EMBASE, Medline, and Micromedix. Both reported and theoretical adverse effects were extensively
reviewed.
Results: Of the 1500 publications reviewed, 100 papers were retrieved and included in the review. Although some
ingredients in PTMC products might cause adverse reproductive effects at high systemic doses, these doses are
hundreds to thousands fold greater than those systemically available from topical use at the recommended
maximum dose (i.e. 10 g/day).
Conclusions: This study provides evidence that, when used as indicated, PTMC is apparently safe for pregnant
women and their unborn babies as well as for breastfed infants.
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The rates of muscle aches, sprains, and inflammation are
significantly increased during pregnancy, often resulting in
lower back and neck pain [1]. These pain symptoms tend
to increase as pregnancy advances through the first, sec-
ond, and third trimesters [1-4]. It has been estimated that
approximately two-thirds of pregnant women in the* Correspondence: gkoren@sickkids.ca
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unless otherwise stated.United States experience lower back pain, and more than
50% of them receive little or no treatment from their phy-
sicians [4,5]. This could be attributed to the fears of fetal
risks associated with the use of systemically administered
agents such as non-steroidal anti-inflammatory drugs.
Therefore, the use of topical analgesics seems attractive
for women afraid of adverse effects of oral medications.
Among topical analgesics, the Professional Therapy
MuscleCare (PTMC) has been shown to be effective in
alleviating muscle pain in a randomized, placebo-
controlled double-blind study of five topical analgesics
[6]. The line of PTMC products includes an ointment
and Roll-on gel containing ingredients that are topicallyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Amounts received by a 70 kg person applying
10 g of PTMC ointment or roll-on gel




mg mg/kg mg mg/kg
MSM 500 7.14 50 0.71
Camphor 300 4.28 300 4.28
Menthol 400 5.71 1000 14.28
Methyl salicylate 100 1.43 – –
Glucosamine sulfate 300 4.28 20 0.28
Sodium chondroitin sulfate 10 0.14 10 0.14
Eucalyptus Oil 50 0.71 300 4.28
Grape seed oil 100 1.43 – –
Vitamin E 100 1.43 – –
Thymol 20 0.28 – –
Sea cucumber extract 100 1.43 – –
Aloe barbadensis leaf juice 10 0.14 – –
Peppermint oil – – 300 4.28
Boswellia – – 70 1.0
Ilex – – 70 1.0
Magnesium 20 0.28 10 0.14
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muscle strain/spasm, and arthritis during pregnancy. To
date, the safety of PTMC ingredients during pregnancy
and lactation has not been reviewed. Thus, the aim of
the current article was to review the available evidence
related to fetal safety of PTMC ingredients and to create
an evidence-based framework for PTMC use during
pregnancy and lactation.
Physiological changes during pregnancy and the need for
topical analgesics
Pregnancy is associated with continuous physiological
changes that lead to higher rates of lower back and neck
pains [2-4,7,8]. These changes include weight gain, hor-
monal changes, and muscle separation in the area of the
sacroiliac joint. While the hormone relaxin usually re-
laxes ligaments in the pelvic area allowing the birth
process to take place [9], this hormone also relaxes liga-
ments supporting the spine, often leading to severe pain
during pregnancy. This situation is exacerbated by separ-
ation of muscles secondary to the increased size of the
uterine. The emotional stress might also contribute to
back spasms in pregnancy [10]. Pain increases as a result
of weight gain burdening the muscles from the neck
down, often leading to stiffness. Taking into consideration
the large number of pregnant women refusing the use of
systemic analgesics, there is an urgent need to evaluate
the safety of topical analgesics such as PTMC [4,5].
Route of exposure and topical use of PTMC
In this article, we retrieved all existing toxicological in-
formation regarding PTMC ingredients in the context of
the concentrations of each ingredient within these prod-
ucts. Where available, an attempt has been made to
focus on studies employing topical rather than oral ex-
posure, and to highlight studies carried out on humans
rather than animals or in vitro cell culture models. How-
ever, since PTMC products have not been directly studied
in vitro or in vivo, their toxicities need to be extrapolated
from studies examining PTMC’s ingredients either alone
or in studies using similar ingredients to those found in
PTMC products. It is important to bear in mind that com-
pounds in similar creams may be presented at different
ratios, which might influence the properties of these prod-
ucts. Thus, when examining each ingredient, it is import-
ant to remember that these ingredients were invariably
studied at different concentrations in animal studies and,
thus, extrapolation of data from other creams to PTMC
must be done cautiously. Taking into consideration that
the principal source of human exposure to PTMC prod-
ucts is through the skin, these products are strictly
intended for external use at recommended maximal dose
of 10 g/day. Table 1 summarizes the amounts received by
a 70 kg person applying 10 g of PTMC.Methods
Search method
A professional librarian with expertise in the areas of
systematic reviews carried out literature searches using
Web of Science, EMBASE, Medline, and Micromedix.
The terms used in systematic search were the names of
PTMC ingredients and “reproductive effect” with no lan-
guage restrictions. Studies were selected based reporting
toxicological, developmental, and reproductive effects of
PTMC ingredients. We excluded all studies that did not
mention safety of these ingredients. Of the 1500 publica-
tions reviewed, 100 papers were retrieved and included
in the review (Figure 1 Study flowchart).
Results and discussion
Toxicological, developmental, and reproductive effects of
PTMC
The PTMC ingredients are mainly classified as anti-
inflammatory, analgesics, circulation enhancers, or tissue
repair ingredients (Tables 2 and 3). These ingredients
were reviewed with respect to general, developmental,
and reproductive adverse effects reported in human and/
or animal studies (Table 4 summarizes these adverse ef-
fects of ingredients of PTMC).
Dimethyl sulfone (Methylsulfonylmethane or MSM)
Several studies showed no adverse reactions when a
cream containing dimethyl Sulfone (MSM) was applied
topically on a daily basis over four weeks [11]. Treatment
Figure 1 Study flow chart.
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verse effects [11]. Similarly, adverse drug reactions were
minimal in a study that evaluated the efficacy of MSM in
reduction of symptoms associated with allergic rhinitis
[12]. In this study, 15 males and 35 females between the
ages of 21 and 60 received 2.6 g of MSM once daily forTable 2 Active ingredients of PTMC ointment and roll-on gel
Active ingredients Purpose
MSM (methylsulfonylmethane) Topical: anti-inflammatory, Oral: relieves ost
Menthol Topical: analgesic and anesthetic
Camphor Topical: analgesic
Glucosamine Topical: analgesic, Oral: relieves joint pain, p
Vitamin E Anti-oxidant protection of skin
Sea Cucumber Tissue repair, antioxidant
Oil of Wintergreen Topical: analgesic, anti-inflammatory
Eucalyptus Leaf Oil Topical: analgesic, counter-irritant, skin pen
Grape Seed Oil Healing damaged tissue
Aloe Barbadensis Leaf Topical: analgesic
Thymol Topical: analgesic, anesthetic
Chondroitin Skin conditioning
Peppermint Oil Topical: analgesic
Boswellia Topical: anti-inflammatory
Ilex Skin conditioning
Magnesium chloride Viscosity controlling30 days and a subset of subjects further received 5.2 g for
additional 14 days. Although the recommended dose for
dietary supplementation of MSM is 1 to 6 g/day, there are
no peer-reviewed studies on its long-term use in humans.
MSM was reported to cause low oral toxicity in rats (LD50




eoarthritis pain 5.0% 0.50%
4.0% 10.0%
3.0% 3.0%
rotects against cartilage deterioration 3.0% 0.20%
1.0% Not in roll-on
1.0% Not in roll-on
1.0% Not in roll-on
etration 0.5% 3.0%
1.0% Not in roll-on
0.1% Not in roll-on
0.2% Not in roll-on
0.1% 0.1%
Not in ointment 3.0%
Not in ointment 0.7%
Not in ointment 0.7%
0.2% 0.1%
Table 3 Inactive ingredients of muscle care ointment and roll-on gel
Inactive ingredients Purpose Content % (Ointment) Content % (Roll-on)
Cetyl alcohol Viscosity increasing 6.0% Not in roll-on
Stearyl alcohol Emollient, thickening agent 4.0% Not in roll-on
Glycerin Reduces irritation, prevents dehydration 4.0% 0.6%
Polysorbate-20 Surfactant 1.0% Not in roll-on
Urea Hydrating, penetration enhancer 1.0% Not in roll-on
Water Hydrating, penetration enhancer 55.1% 8.90%
Sepigel 305 Increases viscosity, stability, and shine 2.0% Not in roll-on
Optiphen Plus Preservative (for paraben-free use) 0.8% Not in roll-on
Acrylates Copolymer Binder/film former Not in ointment 9.0%
Propylene Glycol Skin conditioning, penetration enhancer Not in ointment 3.0%
Denatured alcohol Astringent, masking Not in ointment 56.25%
Triethanolamine Emulsifying agent Not in ointment 0.9%
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events in rats [13]. Although some studies reported that
MSM can cross the placenta resulting in higher concen-
trations in the fetal plasma [14], to date, there have been
no human data on adverse reproductive effects. Oral ad-
ministration of MSM to pregnant rats at doses of 50 to
1000 mg/kg/day during organogenesis did not induce fetal
anomalies. These studies concluded that No Observed
Adverse Effect Level (NOAEL) for maternal and develop-
mental toxicity is 1 g/kg/day [15,16].
Camphor
Poisoning cases after topical use of camphor have been
reviewed for adults and children between 1990 and 2003
[17]: 1) A 15-month-old boy who crawled through
spilled camphor spirits developed ataxia and generalized
convulsions. 2) A 2-month-old girl developed elevated
serum transaminase following application of Vicks
VapoRub to her chest and neck (4.8% camphor, 3 times
a day for 5 days). 3) A 25-month-old boy developed de-
lirium, visual hallucinations, and urinary incontinence
after his chest was “soaked” in more than 1 ounce of
camphorated oil for 80 hours (6.4 g of camphor). 4) A 9-
month-old girl with 20% body surface area burns was
treated with a dressing containing 9.6% camphor for
24 hours (estimated exposure to 15 g camphor) and de-
veloped severe toxicity including convulsions. 5) A 72-
year-old woman developed granulomatous hepatitis
following dermal application of five containers of Vicks
VapoRub Ointment. After discontinuation of the use,
these problems were resolved.
Of importance, several studies have shown that cam-
phor has a low absorption rate (less than 0.1%) from
medicated patches containing 46.8 mg camphor in con-
junction with 37.4 mg menthol and 74.88 mg methyl sa-
licylate [18]. Orally, the exposure of children (ages of
14 months - 5 years old) to 0.7-1.5 g of camphor wasassociated with fatal symptoms [19]. Another study has
examined the administration of camphor to 80 postpar-
tum women who were injected 195 mg camphor in the
first day followed by daily injections of 97 mg over
3 days. In this study, only one patient developed adverse
events (nausea and vomiting) [17]. Thus, the US FDA
has set a limit of 11% camphor in different products, as
ingestion of larger quantities may cause adverse effects
such as seizures, confusion, irritability and neuromuscu-
lar hyperactivity. The LD50 in mice is 1.3 g/kg.
With respect to reproductive effects, studies showed
that camphor can cross the human placenta when
ingested orally [20]. Topically, the frequency of birth de-
fects was not greater than baseline among 168 pregnan-
cies where camphor was used in the first trimester as
well as among 763 women who used camphor anytime
during pregnancy [21]. There was no increase in the in-
cidence of congenital abnormalities when camphor was
used at high oral doses in pregnant rats and rabbits
(100–1000 mg/kg/day and 50–681 mg/kg/day) [22-24].
Although few reports of camphor poisoning are avail-
able, to date, there are no reported adverse fetal effects
[20,25-27]. It has been reported that women who used a
suppository containing camphor during pregnancy had
infants with an increased average birth weight and gesta-
tional age [28].
Menthol
The FDA has approved methanol as a safe chemical for
external use with concentrations up to 16% [29]. Acute
dermal toxicity was reported with LD50 of 5 g/kg in rab-
bits. Orally, the LD50 values were 2.9 g/kg and 3.1 g/kg
in rat and mice, respectively. It has been reported that
rats given menthol at 200 mg/kg/day for 28 days had in-
creased liver weights and vacuolization of hepatocytes
[30]. With respect to reproductive effects, there has been
no study examining menthol safety in humans. There
Table 4 Summary of general and reproductive effects of PTMC products
Ingredient Species General toxicology Reproductive effects References
Methylsulfonylmethane Human • Topically, there are no adverse reactions. • Till date, no data. [11-16]
• There are no studies on long-term use.
Animal • Orally, it has low toxicity. • Do not induce structural or fetal anomalies.
• Long-term use did not cause adverse events.
Camphor Human • Topically, poisonings were reported in
children and adults.
• Topically, the frequency of birth defects
was less.
[17-28]
• Orally, it caused fatal symptoms in children. • Orally, cross the human placenta, however,
till date, there are no adverse fetal effects.
Animal • The oral LD50 = 1.3 g/kg in mice. • Orally, there are no congenital abnormalities
in rats and rabbit.
Menthol Human • Topically, it is safe. • Till date, no data. [29-31]
Animal • Topically, acute dermal toxicity was
reported with LD50 = 5 g/kg in rabbit.
• There is no teratogenic effect in mice, rats,
hamsters, or rabbits.
• Orally, toxicity was reported at LD50 = 2.9 g/kg
and 3.1 g/kg in rat and mice, respectively.
Wintergreen Oil Human • In cosmetics, methyl salicylate is safe, however,
might cause local necrosis.
• Till date, no data. [32-42]
• There are some reports for tinnitus, diplopia,
shortness of breath, and respiratory alkalosis.
Animal • Topically, sub-chronic exposure might lead
to kidney damage in rats.
• It is associated with increased risk
of abnormalities.
Glucosamine Sulfate Human • Topically, it did not cause toxicity or
adverse effects.
• There is no increase in risk of malformations. [43-47]
Animal • Topically, it is considered safe. • Teratogenic effects were not reported in
mice or rabbits exposed to glucosamine.
Sodium Chondroitin
Sulfate
Human • Topically, there are no adverse events. • Till date, no data [43,48-52]
• It interferes with progression of osteoarthritis.
Animal • The oral LD50 for mice is greater than 10 g/kg. • There is increased risk of cleft palate and
tail abnormalities in mice.
• Orally, there are no adverse effects in mice
and rabbits.
Eucalyptus Leaf Oil) Human • Topically, it is safe. • Till date, no data. [53-56]
• A report of fever and seizure-like motor
activity -in slurred speech, ataxia, and muscle
weakness were reported in children.
• Orally, there are minor side effects.
Animal The oral LD50 = 2.5 g/kg in rats. • There are no adverse outcomes in mice.
Grape Seed Oil Human • Topically, it is safe. • Till date, no data. [57-60]
Animal • There are no safety issues associated with
acute and chronic safety studies rats
• The grape seed extract was non-mutagenic
in mice.
• Several reports showed that LD50 for dermal
application is greater than 2 g/kg in rats.
Vitamine E Human • Topically, it is safe. • There are no risks of stillbirth, perinatal
death, preterm birth, intrauterine growth
restriction, or mean birth weight.
[61-66]
• High doses were associated with reduction
in birth weight.
Animal • Topically, it is safe. • Malformation was not greater than expected
in offspring of rats and mice.
[67-71]
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Table 4 Summary of general and reproductive effects of PTMC products (Continued)
Thymol Human • Topically, it is safe. • It is not associated with increased risks of
birth defects.
[21,72-76]
• It is toxic to mucous membranes and to
kidneys, liver, and central nervous system.
Animal • Topically, it is safe. • Might cause adverse reproductive effects.
Sea Cucumber Extract Human • Topically, it is safe • Till date, no data. [77-81]
Animal • Topically, it is safe. • Till date, no data.
Aloe Barbadensis Leaf
Juice
Human • Topically, it is safe, however, not recommended
for children under age of 12 years.
• Orally, it is not recommended in pregnancy
or lactation.
[82-88]
• Orally, there are adverse effects in rare cases.
Animal • Topically, it is safe. • Teratogenic effects have been reported
with high oral doses in rats.
Peppermint Oil Human • Topically, it caused skin irritation with
frequent use of oil.
• It induces menstruation and, thus, it is
not recommended at high oral doses
during pregnancy.
[83,89-91]
• Orally, enteric-coated capsules were not
associated with adverse reactions.
• There is insufficient evidence to determine
the safety of peppermint oil during lactation.
Animal • The oral LD50 was reported at 2490 mg/kg
in mice and at 2426 mg/kg in rats.
• Orally, the LD50 was 2490 mg/kg in mice
and 2426 mg/kg in rats.
• The peppermint oil was used to induce
menstruation and it is not recommended
at high oral doses in pregnancy.
Boswelli, and
Magnesium chloride
Human • Topically, boswelli is associated with dermatitis. • Orally, there is lack of evidence on safe use
of boswelli during pregnancy and lactation.
[92-99]
• Orally, boswelli is associated with
gastrointestinal effects including, nausea,
abdominal fullness, and epigastria.
• Similarly, magnesium chloride studies failed to
demonstrate risks of birth defects to the fetus.
• Orally, magnesium chloride is not
recommended for patients with
renal impairment.
• Both magnesium and ilex are safe for
topical use.
Animal • Topically, boswelli is safe in mice, rats
and monkeys.
• There is lack of evidence on safe use during
pregnancy and lactation.
• Orally, boswelli was not associated with
mortality in rat and mice.
• In rat and monkey, there was no change
in behavior, clinical, biochemical, or
pathological data when boswelli was
used orally.
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rats, hamsters, or rabbits receiving doses ranging from 1
to 106 times the accepted daily intake in humans [31].
Wintergreen oil (Gaultheria procumbens/Methyl salicylate)
Although prolonged skin contact with methyl salicylate
may cause dermatitis, methyl salicylate is generally safe
in topical formulations [32]. Local necrosis occurred in a
62-year-old man after 1 day use of Bengay (18.3% methyl
salicylate and 16% menthol) [33]. The Bengay was applied
to the forearms and legs along with periodic heating of the
area with a heat pad [33]. There was evidence of tinnitus,
diplopia, shortness of breath, mixed metabolic acidosis,and respiratory alkalosis [33]. The lowest lethal oral dose
of methyl salicylate was reported in women at 355 mg/kg,
in men at 101 mg/kg, and in children at 228 mg/kg. Of
importance, a teaspoon or less of wintergreen oil has been
implicated in several deaths of children under the age of
6 years [34]. It has been reported that dermal exposure to
methyl salicylate was associated with LD50 of 2 g/kg [32].
Both the rate and extent of absorption through the skin
are dependent on the exposed area as determined in
equine skin [35]. The oral LD50 is 887 mg/kg in rats.
With respect to reproductive effects, administration of
methyl salicylate (up to 0.5 mL) in rats during organo-
genesis increased the rate of abnormalities, particularly
Alsaad et al. BMC Complementary and Alternative Medicine  (2015) 15:40 Page 7 of 11of the central nervous system. This dose represents 5
times the lethal adult human dose [36]. It has been re-
ported that pregnant hamsters treated orally or topically
with 175 mg/100 g methyl salicylate exhibited central
nervous system teratogenicity [37]. However, there is no
conclusive evidence that salicylate is teratogenic in
humans [38]. When methyl salicylate was given at doses
of (200, 250, or 300 mg/kg/day), there was a reported al-
teration in renal pelvis and urine formation in rats [39].
However, the topical application of methyl salicylate in
petroleum-based grease did not cause congenital defects
when used at doses up to 6000 mg/kg/day [40]. High
doses of methyl salicylate (such as 250 and 500 mg/kg/
day) were reported to increase the litter size. However,
these doses did not result in congenital abnormalities in
mice. The lower doses (100 mg/kg/day) had no observ-
able adverse reproductive effects [41]. Importantly, the
doses in these studies were significantly higher than the
adult lethal human dose on mg/kg basis. The American
Academy of Pediatrics recommended the use of salicy-
lates with caution during breastfeeding [100].
Glucosamine sulfate
It has been shown that topical application of a cream
containing 0.3% glucosamine sulfate did not cause ad-
verse effects [43]. In large clinical trials, oral glucosa-
mine reduced progression of knee osteoarthritis and
prevented joint space narrowing [44,45]. Although glu-
cosamine is widely used in veterinary medicine [46], no
teratogenic effects were reported in mice or rabbits. In a
prospective controlled study of 34 pregnant women ex-
posed to glucosamine during the first trimester, there
was no increase in risk of major malformations [47].
Sodium chondroitin sulfate
Several studies failed to report significant adverse events
with topical use of a cream containing 0.78% chondroitin
sulfate [43]. The use of chondroitin in combination with
glucosamine is effective in treatment of knee pain since
chondroitin enhances the pain-relieving action of glu-
cosamine [48-50]. It has been reported that chondroitin
and glucosamine sulfate attenuate progression of osteo-
arthritis [51]. Orally, the LD50 was greater than 10 g/kg
in mice. However, mice injected with 1 mL of 2% chon-
droitin on day 9, 10, or 11 of gestation exhibited an in-
creased rate of cleft palate and tail abnormalities in the
offspring [52]. To date, there has been no human study
on the effects of chondroitin sulfate during pregnancy
and lactation.
Eucalyptus leaf oil (Eucalyptus globulus/1, 8-cineole)
Eucalyptus leaf oil is widely used in mouthwashes and
cough suppressants. However, to date, there have been
no reported deaths caused by topical use of eucalyptusoil. There was only a report of fever and seizure-like
motor activity in a 2-year-old boy rubbed with eucalyp-
tus oil [53]. A 6-year-old who was exposed to eucalyptus
oil exhibited slurred speech, ataxia, and muscle weakness
[54]. There were minor adverse effects in two 76-year-
old patients ingesting 600 mg of eucalyptus daily for
7 days [55]. Orally, the LD50 was 2.5 g/kg in rats. There
has been no adverse outcome in mice injected on days 6
and 15 of gestation [56]. Also, there has been no evi-
dence of adverse reproductive effects of eucalyptus oil in
humans.
Grape seed oil (Vitis vinifera)
Procyanidin B-2, a component of Grape Seed Extract,
was found to be safe for topical use based on mutagenic
and ocular irritation assays [57]. The proanthocyanidin
extract is regarded safe for consumption at 1.4 g/kg/day
[58]. There are no safety issues identified in acute and
chronic studies of oral and dermal exposure to the
proanthocyanidin extract in animal studies [59]. The
grape seed extract was also non-mutagenic in mice [60].
Several reports showed that the LD50 for dermal applica-
tion is greater than 2 g/kg in rats [59]. With subcutane-
ous injection, the lethal dose of procyanidin B-2 was
greater than 2 g/kg [57]. However, to date, there have
been no human data on the reproductive effects of grape
seed oil.
Vitamin E (Alpha-Tocopherol acetate)
Vitamin E is safe for topical use in different creams aim-
ing to protect the skin against ultraviolet rays [61].
There have been four randomized double-blinded trials
involving 566 women at risk of pre-eclampsia who re-
ceived high doses of vitamin E in the second and third
trimesters of pregnancy. In these trials, there was no dif-
ference between women exposed to high doses vitamin
E and women exposed to placebo in terms of risk for
stillbirth, perinatal death, preterm birth, growth restric-
tion, or birth weight [62-65]. Similarly, among 82 infants
born to women who received high doses of vitamin E
(400 mg/day), there was no increase in malformations or
miscarriages [62-65]. Only one infant was born with om-
phalocele [66]. The frequency of malformations was not
increased in the offspring of rats and mice treated with
vitamin E at doses hundreds to thousands times of the
human doses [67-71].
Thymol
Thymol is considered safe in topical formulations at a
concentration of 0.5% [72]. However, thymol was toxic
to mucous membranes as well as to the kidneys, liver,
and central nervous system [72]. The oral LD50 was
980 mg/kg in rats, 640 mg/kg in mice, and 880 mg/kg in
guinea pigs. Thymol was not associated with increased
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posed in the first trimester of pregnancy [21]. Although
thymol was used previously as part of an abortifacient
paste to induce the abortion [73-75], only one fatality
was reported with the paste use [76].
Sea cucumber extract (SCE)
It has been reported that topical exposure of gingival tis-
sue to sea cucumber extract (SCE) over three months
was safe [77]. Also, the use of SCE as an oral daily sup-
plement for six months was not associated with any ad-
verse effects. Although SCE has been shown to have
potent anti-tumor effects in vitro [78-81], to date, there
has been no evidence on safety of SCE during pregnancy
and lactation.
Aloe Barbadensis leaf juice
Aloe is considered safe in topical formulations since
hypersensitivity reaction is relatively rare [82]. Although
the aloe is used in adults, it is not recommended for
children under age of 12 years [83]. The aloe is used or-
ally to relieve constipation and adverse effects were re-
ported only in rare cases [83]. A 56-year-old woman
developed hypothyroidism after high doses of aloe taken
for 11 months [83]. The thyroid function tests had nor-
malized 16 months after discontinuation of treatment
[84]. Another 73-year-old woman developed acute hepa-
titis after ingesting aloe powder every 2 to 3 days for
5 years [85]. The liver function tests and biopsies were
consistent with findings of drug-induced acute hepatitis
and completely resolved after discontinuation of aloe use
[85]. Similarly, a 24-year-old male developed acute drug-
induced hepatitis after 3 weeks of daily use of oral aloe
extract where the clinical symptoms resolved 7 days
after the aloe was discontinued [86]. Thus, aloe is not
recommended orally during pregnancy and/or lactation
[87]. Teratogenic effects have been reported when aloe
was given at high oral doses to rats [88]. However, there
is no contraindication for topical use during pregnancy
and/or lactation.
Peppermint oil
Peppermint oil is commonly used and may cause skin ir-
ritation due to the presence of menthone [89]. There are
no specific therapeutic or toxic dose rages for oral use.
The enteric-coated capsules of the oil have been used to
treat irritable bowel syndrome at doses of 0.2 to 0.4 mL
three times daily without adverse events [90,91]. Also,
the average daily dose of 6 to 8 drops of the oil caused
no adverse effects [83]. According to the world health
organization (WHO), peppermint oil is considered a safe
additive at doses up to 4 mg/kg. The oral LD50 is
2490 mg/kg in mice and 2426 mg/kg in rats. The pepper-
mint oil has also been used to induce menstruation and itis not recommended at high oral doses during pregnancy
[90]. Although there is insufficient evidence on safety of
the oil during lactation, it has been suggested that amount
of the oil in OTC products is likely to be safe for breastfed
infants [90].
Boswellia and ilex
Boswellia is frequently used in topical formulations to
treat osteoarthritis. However, dermatitis was reported in
4 of 62 patients who used topical preparations contain-
ing boswellia [92,93]. The boswellia is recommended for
oral use at 400 mg three times daily for arthritis and
300 mg three times daily for asthma [94,95]. The com-
mon oral adverse effects are nausea, abdominal fullness,
and epigastric pain [96]. Both acute and chronic toxicity
studies were conducted in mice, rats, and monkeys. In
these studies there was no mortality in rats and mice
that received doses up to 2 g/kg. Similarly, there were
no changes in behavior, clinical, biochemical, or patho-
logical data with oral daily use of boswellia in rats and
monkeys [97]. With respect to reproductive effects, there
is insufficient evidence on safety of boswellia during
pregnancy and lactation. Similar to boswellia, there is in-
sufficient scientific evidence on safety of ilex during
pregnancy and lactation.
Magnesium (Magnesium chloride)
Magnesium is commonly used in topical preparations as
well as a dietary supplement in doses raging from 54 to
483 mg/day [98]. It is often used to treat hypomagnes-
emia intravenously as 4 g in 250 mL D5W and up to a
maximum rate of 3 mL/min [99]. However, magnesium
chloride is not recommended for oral ingestion in pa-
tients with renal impairment [99]. The FDA has listed
magnesium chloride as pregnancy category A, which
means “Adequate and well-controlled studies in preg-
nant women have failed to demonstrate a risk to the
fetus in the first trimester of pregnancy (and there is no
evidence of a risk in later trimesters)” [99].
Synthesis of findings and conclusions
Pregnant women frequently hesitate to use systemic an-
algesics for treatment of pregnancy-related pain due to
strong perception of teratogenic risks. Among the avail-
able topical analgesics, PTMC products are used to alle-
viate muscle and joint pains. Although some active
ingredients in PTMC are relatively toxins when used or-
ally at high doses, these doses are thousands of times
larger than those available systemically after topical use
at the recommended maximum dose (i.e. 10 g/day).
Thus, this review provides evidence that, when used as
indicated, PTMC is apparently safe for pregnant women
and their unborn babies as well as for lactating women.
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